Veracyte Inc (VCYT) - Net Assets
Based on the latest financial reports, Veracyte Inc (VCYT) has net assets worth $1.39 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.49 Billion) and total liabilities ($97.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Veracyte Inc (VCYT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.39 Billion |
| % of Total Assets | 93.41% |
| Annual Growth Rate | 43.27% |
| 5-Year Change | 19.43% |
| 10-Year Change | 2097.98% |
| Growth Volatility | 270.31 |
Veracyte Inc - Net Assets Trend (2011–2025)
This chart illustrates how Veracyte Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Veracyte Inc (VCYT) total market value.
Annual Net Assets for Veracyte Inc (2011–2025)
The table below shows the annual net assets of Veracyte Inc from 2011 to 2025. Also explore VCYT shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.31 Billion | +11.36% |
| 2024-12-31 | $1.18 Billion | +12.63% |
| 2023-12-31 | $1.04 Billion | -2.89% |
| 2022-12-31 | $1.08 Billion | -1.94% |
| 2021-12-31 | $1.10 Billion | +160.31% |
| 2020-12-31 | $421.23 Million | +75.91% |
| 2019-12-31 | $239.46 Million | +200.24% |
| 2018-12-31 | $79.75 Million | +114.25% |
| 2017-12-31 | $37.23 Million | -37.52% |
| 2016-12-31 | $59.58 Million | +16.25% |
| 2015-12-31 | $51.25 Million | +23.87% |
| 2014-12-31 | $41.37 Million | -26.70% |
| 2013-12-31 | $56.44 Million | +1051.66% |
| 2012-12-31 | $4.90 Million | -42.54% |
| 2011-12-31 | $8.53 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Veracyte Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33621000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.00K | 0.01% |
| Other Comprehensive Income | $-8.21 Million | -0.63% |
| Other Components | $1.70 Billion | 129.46% |
| Total Equity | $1.31 Billion | 100.00% |
Veracyte Inc Competitors by Market Cap
The table below lists competitors of Veracyte Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nuode Investment Co Ltd
SHG:600110
|
$3.10 Billion |
|
Schneider Electric Infrastructure Limited
NSE:SCHNEIDER
|
$3.10 Billion |
|
Arcus Biosciences Inc
NYSE:RCUS
|
$3.10 Billion |
|
LXP Industrial Trust
NYSE:LXP
|
$3.10 Billion |
|
Concentra Group Holdings Parent, Inc.
NYSE:CON
|
$3.09 Billion |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
$3.09 Billion |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
$3.09 Billion |
|
SF Diamond
SHE:300179
|
$3.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Veracyte Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,175,966,000 to 1,309,576,000, a change of 133,610,000 (11.4%).
- Net income of 66,353,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 27,878,000.
- Other factors increased equity by 39,379,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $66.35 Million | +5.07% |
| Other Comprehensive Income | $27.88 Million | +2.13% |
| Other Changes | $39.38 Million | +3.01% |
| Total Change | $- | 11.36% |
Book Value vs Market Value Analysis
This analysis compares Veracyte Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 64.07x to 2.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.60 | $38.50 | x |
| 2012-12-31 | $0.35 | $38.50 | x |
| 2013-12-31 | $13.57 | $38.50 | x |
| 2014-12-31 | $1.91 | $38.50 | x |
| 2015-12-31 | $1.98 | $38.50 | x |
| 2016-12-31 | $2.07 | $38.50 | x |
| 2017-12-31 | $1.10 | $38.50 | x |
| 2018-12-31 | $2.15 | $38.50 | x |
| 2019-12-31 | $5.19 | $38.50 | x |
| 2020-12-31 | $7.91 | $38.50 | x |
| 2021-12-31 | $16.15 | $38.50 | x |
| 2022-12-31 | $15.03 | $38.50 | x |
| 2023-12-31 | $14.37 | $38.50 | x |
| 2024-12-31 | $15.05 | $38.50 | x |
| 2025-12-31 | $16.25 | $38.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Veracyte Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.83%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.07x
- Recent ROE (5.07%) is above the historical average (-61.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -169.34% | -546.12% | 0.25x | 1.23x | $-15.30 Million |
| 2012 | -380.51% | -160.38% | 0.61x | 3.89x | $-19.14 Million |
| 2013 | -45.32% | -116.89% | 0.27x | 1.41x | $-31.22 Million |
| 2014 | -70.99% | -76.91% | 0.59x | 1.57x | $-33.51 Million |
| 2015 | -65.76% | -68.08% | 0.66x | 1.47x | $-38.83 Million |
| 2016 | -52.63% | -48.18% | 0.64x | 1.70x | $-37.32 Million |
| 2017 | -83.29% | -43.09% | 0.91x | 2.11x | $-34.73 Million |
| 2018 | -28.84% | -25.00% | 0.76x | 1.51x | $-30.97 Million |
| 2019 | -5.26% | -10.47% | 0.44x | 1.15x | $-36.54 Million |
| 2020 | -8.29% | -29.71% | 0.26x | 1.09x | $-77.03 Million |
| 2021 | -6.89% | -34.42% | 0.18x | 1.08x | $-185.21 Million |
| 2022 | -3.40% | -12.33% | 0.26x | 1.08x | $-144.08 Million |
| 2023 | -7.13% | -20.61% | 0.32x | 1.07x | $-178.81 Million |
| 2024 | 2.05% | 5.41% | 0.34x | 1.11x | $-93.46 Million |
| 2025 | 5.07% | 12.83% | 0.37x | 1.07x | $-64.60 Million |
Industry Comparison
This section compares Veracyte Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $606,666,780
- Average return on equity (ROE) among peers: -71.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Veracyte Inc (VCYT) | $1.39 Billion | -169.34% | 0.07x | $3.10 Billion |
| Agilent Technologies Inc (A) | $3.24 Billion | 21.14% | 2.00x | $43.50 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $1.66 Million | -167.28% | 1.68x | $12.75 Million |
| Applied DNA Sciences Inc (APDN) | $6.86 Million | -187.45% | 0.19x | $3.99 Million |
| Biodesix Inc (BDSX) | $19.73 Million | -218.78% | 2.86x | $285.72 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-4.04 Million | 0.00% | 0.00x | $17.63 Million |
| Biocept Inc. (BIOCQ) | $37.48 Million | -7.53% | 0.61x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.42 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.85 Billion | -43.17% | 0.23x | $109.91 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $12.65 Million | -97.17% | 0.21x | $9.42 Million |
About Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test… Read more